GLP-1 and Kidney Function: What Mounjaro Users Should Know (October 2026)

01 · The short answer

What GLP-1 medicines mean for your kidneys

First, Mounjaro is not known to damage the kidneys or liver directly, and no dose adjustment is needed for mild to moderate kidney or liver impairment.¹ Second, there is an indirect risk worth taking seriously: severe vomiting or diarrhoea can cause dehydration, which can strain the kidneys. People with severe impairment need individual prescriber assessment.¹³

The medicine we supply, Mounjaro, is licensed in the UK for weight management in adults and for type 2 diabetes. If a specialist suggests a GLP-1 medicine as part of your kidney care, that is a decision for your kidney team, based on your own results. Our guide on tirzepatide and kidney function goes further into this.

02 · Your decision

The decisions you are actually facing

• You have healthy kidneys and are considering Mounjaro. The product information does not flag a direct kidney concern. Your main job is to stay hydrated, especially in the early weeks and after each dose increase, when stomach side effects are most likely to cause trouble.
• You have known kidney impairment. Mild to moderate impairment does not need a dose change according to the product information. Severe impairment needs individual assessment. Tell the prescriber about it in your consultation, and tell your kidney team that you are considering treatment.
• You are hoping Mounjaro will protect your kidneys. That is a question for your specialist.

Whichever applies, disclose your full medical history and medicine list. A prescriber will assess your BMI, medical history and current medicines before deciding whether Mounjaro is suitable.¹ Payment is taken when you place the order; if the prescriber decides the treatment is not suitable, the order is refunded automatically in full.

03 · What to do next

Where to go from here

If you want to read more about how weight loss and metabolic health fit together, our weight loss clinic hub explains the treatment pathway. If you are ready to see whether you are suitable, the Mounjaro pen page starts the free consultation.

If you have kidney disease, speak to your GP, kidney nurse or specialist before you order, and let them know what you plan to take. That conversation costs nothing and is the safest route.

04 · How GLP-1 works

How GLP-1 medicines work in the body

GLP-1 is a natural gut hormone, and GLP-1 medicines copy its action. To understand why people ask about kidneys at all, it helps to know what these medicines do.

Tirzepatide, the active ingredient in Mounjaro, activates two natural gut-hormone receptors at once: GIP and GLP-1. Together these help regulate appetite, slow how quickly the stomach empties, and improve the way the body responds to insulin.¹ In practice, most people feel fuller sooner and less hungry between meals, which supports a reduced-calorie diet. This dual action is what distinguishes Mounjaro from single-action GLP-1 medicines such as semaglutide (Wegovy and Ozempic).

None of that describes an effect on the kidneys. The mechanism is about appetite, stomach emptying and the way the body handles insulin. That matters, because it explains why the product information focuses on weight management and type 2 diabetes, and why kidney effects are discussed in terms of indirect risks rather than direct action.

Why the digestive effects matter for kidneys

Slower stomach emptying is part of how the medicine works, and it is also why nausea, sickness and loose stools are common when treatment starts or a dose goes up. Most people find these settle as the body adjusts, but they are the link between this medicine and your kidneys. If vomiting or diarrhoea becomes severe, the body loses fluid. The kidneys depend on enough fluid to do their job, so the practical advice is always about fluids first.

One medicine class, different products

The GLP-1 family includes several medicines with different licences, doses and schedules. Wegovy is a once-weekly semaglutide pen with a ladder of 0.25mg, 0.5mg, 1mg, 1.7mg and 2.4mg. Liraglutide, supplied at 6mg/ml, is a daily injection. Mounjaro is once weekly and comes in 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg and 15mg strengths. It is natural to assume they all behave alike for the kidneys, but each product has its own licence and product information. Each product has its own product information, and your prescriber should read the one for the exact medicine you are taking.

What this means for you

If you are reading this because a headline told you GLP-1 medicines are good or bad for kidneys, the safest reading is this: the mechanism is metabolic and digestive, the direct kidney risk in Mounjaro's product information is not established, and the indirect risk is dehydration. Anything beyond that belongs in a conversation with a clinician who has your blood results in front of them.

05 · Kidney protection claims

Kidney protection and Mounjaro

You may have read that GLP-1 medicines protect the kidneys, but Mounjaro is not licensed for that. Our guide on whether Mounjaro helps kidney function follows the same principles.

Mounjaro is licensed in the UK for weight management in adults and for type 2 diabetes.¹ Kidney protection is not one of its licensed uses. These are very different things. A medicine that does not harm an organ is not the same as a medicine that protects it.

Indirect effects are not the same as protection

In weight-loss trials, people taking tirzepatide saw average improvements in waist size, blood pressure, cholesterol and blood-sugar measures.² Those are trial-average secondary outcomes, not individual outcomes. It is reasonable for a clinician to consider whether better weight and metabolic health might matter to someone with kidney concerns, but that is a clinical judgement about your situation.

What honest uncertainty looks like

If you have kidney disease and want to know whether a GLP-1 medicine is appropriate for you, your kidney specialist or diabetes team is best placed to say, using your own blood and urine results. Our prescribers will take your kidney history seriously during the consultation, and where your situation needs individual assessment, they will say so.

06 · What the label says

Mounjaro and the kidneys: what the product information says

The product information gives a clear, short statement. Mounjaro is not known to damage the kidneys or liver directly, and no dose adjustment is needed for mild to moderate kidney or liver impairment.¹ People with severe impairment need individual prescriber assessment.¹³

Not known to damage kidneys directly

This wording is careful. It does not say kidney problems cannot happen to anyone taking the medicine. It says the medicine itself is not known to be a direct cause. If you develop kidney trouble while on treatment, the more likely route is something indirect, such as fluid loss, another medicine, or an underlying condition, and your clinician will want to look at all of these.

No dose adjustment for mild to moderate impairment

For many people with mild or moderate kidney impairment, the dosing steps are the same as for anyone else. The usual approach is a gradual step-up, guided by how you feel, with your prescriber reviewing progress. Do not change your own schedule because of kidney concerns; talk to the prescriber.

Severe impairment needs individual assessment

The product information says individual prescriber assessment is needed. In practice, that means a clinician weighs your kidney function, other conditions, other medicines and the reason for treatment. It may be that treatment goes ahead with extra monitoring, or it may be that another route is better. Either outcome is a safe, careful one, and neither is a failure.

What you should always do

Before starting, share your full medical history and medicine list during consultation.¹ Mention any kidney diagnosis, any past hospital stays for dehydration or kidney injury, and any regular medicines, including those bought over the counter. Your kidney team does not need to be bypassed either; telling them you plan to start treatment is sensible and keeps everyone working from the same information.

Our aftercare includes ongoing monthly reviews, dose titration and follow-up assessments by the prescribing team, plus side-effect support. Repeat orders re-check suitability, and nothing is shipped automatically.

07 · Dehydration and kidneys

Dehydration: the practical kidney risk

The most practical kidney risk with Mounjaro is dehydration. Severe vomiting or diarrhoea can cause dehydration, which can strain the kidneys, so keep fluids up and get medical help straight away if you cannot keep fluids down.¹

This is the one area where you have real control, so it is worth making a plan before it happens rather than during a rough day.

When risk is highest

Stomach side effects tend to cluster around the start of treatment and the weeks after a dose increase. That is also when you may be eating less, which can reduce the fluid you take in from food. Hot weather, illness, travel and heavy exercise can add to the fluid you lose. Put these together and you can see how a manageable situation can turn difficult.

A simple routine

• Sip fluids regularly through the day rather than waiting until you are thirsty.
• Keep plain water, or whatever you can tolerate, within reach on injection day and the days after.
• If you are being sick or have diarrhoea, focus on keeping fluids in before worrying about food.
• Get medical help straight away if you cannot keep fluids down; do not wait for it to settle on its own.
• Do not take extra doses or change the schedule to compensate. Ask the prescriber instead.

Other signs that need urgent attention

Serious side effects are uncommon but need urgent attention. Seek immediate medical help for severe, persistent stomach pain that may spread to your back, with or without vomiting, which could be pancreatitis. Also seek immediate medical help for pain in the upper right abdomen, fever or yellowing of skin or eyes, which could be a gallbladder problem, or for signs of a severe allergic reaction such as swelling of the face or throat and difficulty breathing.¹³ If you take insulin or a sulfonylurea alongside Mounjaro, watch for low blood sugar, such as shakiness, sweating or confusion, as your prescriber may need to adjust those medicines.

Reporting

If you think a side effect is linked to your medicine, you can report it through the MHRA Yellow Card scheme.¹⁹ This applies to anything new or unexpected, including changes you are unsure about. Do not wait for certainty before telling your prescriber. If you are worried about passing less urine than usual or feeling very unwell, contact your clinical team or GP, or use 111.

08 · Kidney disease and Mounjaro

Living with kidney disease and considering Mounjaro

If you have chronic kidney disease, the question is not simply whether Mounjaro is allowed but whether it fits your whole picture. Our page on taking Mounjaro with CKD and the overview of GLP-1 medicines for CKD explore this from the reader's side.

Licensed eligibility comes first

Mounjaro is licensed for weight management in adults with a BMI of 30 or above, or a BMI between 27 and 30 with at least one weight-related condition such as high blood pressure, high cholesterol, obstructive sleep apnoea, cardiovascular disease, prediabetes or type 2 diabetes. It must be used alongside a reduced-calorie diet and increased physical activity.¹ People from South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean backgrounds are at higher risk of weight-related health problems at a lower BMI, so clinical thresholds are usually reduced by 2.5 kg/m² for these groups.

Having kidney disease does not, by itself, make you eligible or ineligible. The weight and health criteria still apply, and the prescriber then considers kidney function alongside them.

Who should not take it

You should not take Mounjaro if you are allergic to tirzepatide or any of its ingredients, and it should not be used during pregnancy or while trying to conceive. Mounjaro must not be used during pregnancy, and it should be stopped at least one month before trying to conceive. If you become pregnant during treatment, stop the medicine and tell your prescriber promptly. Your prescriber will take extra care, or may recommend against treatment, if you have a history of pancreatitis, severe gut or digestive disease, diabetic retinopathy, or gallbladder problems.¹ Diabetic retinopathy is worth highlighting for readers with diabetic kidney disease, since the two conditions often occur together.

Thyroid and other disclosures

In rodent studies tirzepatide caused thyroid C-cell tumours; it is not known whether this applies to humans, and no increase has been shown in human trials. Tell your prescriber if you or a close relative have had medullary thyroid cancer or the inherited condition MEN 2. Routine thyroid monitoring is not required for most people.¹

Mild, moderate, severe

For mild to moderate kidney impairment no dose adjustment is needed. For severe impairment, a prescriber must assess you individually. If you do not know how your kidney function is classed, ask your GP or kidney nurse for your latest result and bring it to the consultation. The more complete the picture you give us, the better the decision will be.

Coordinating with your kidney team

A good arrangement is simple: your kidney team looks after your kidney care, our prescribers look after the Mounjaro prescription, and you act as the link. Tell each about the other.

09 · NHS and private routes

NHS and private routes for people with kidney concerns

Many readers ask about NHS access to GLP-1 medicines for kidney disease, and the answer depends on what the medicine is being used for. Our related guide on the best GLP-1 for kidney disease looks at this question further.

Mounjaro on the NHS for weight management

Mounjaro is available on the NHS, but access is being phased in over several years. NICE recommends it for adults with a BMI of at least 35 plus at least one weight-related condition, and the NHS primary-care rollout began in June 2025 with the highest-need groups first, initially BMI 40+ with four or more qualifying conditions.⁴⁶ Full rollout is expected to take years, which is why many people who meet the licensed criteria choose regulated private treatment rather than waiting.

Notice what this describes: access for weight management, based on BMI and weight-related conditions. It is not a kidney-disease pathway. If you have kidney disease and want to know what is available to you locally, your GP or kidney team can tell you.

Why people go private

Some people meet the licensed criteria but are not yet in the NHS groups being treated first. Private prescribing follows the licensed criteria, with the prescriber assessing BMI, medical history and current medicines. That does not make it a shortcut: the same safety questions, including kidney history, apply.

What private treatment involves with us

• A free online consultation, a short health questionnaire with no charge and no obligation.
• Review by a GPhC-registered prescriber, not a scoring script. Payment is taken when you place the order; if the prescriber decides the treatment is not suitable, the order is refunded automatically in full.
• Dispensing by our registered pharmacy, with same-day dispatch when ordered by 3pm.
• Free next-day tracked delivery in discreet, temperature-controlled packaging.

Our supply is official LillyDirect supply, so you receive genuine KwikPens sourced directly from Eli Lilly's UK distribution. You can check our registration on the GPhC register (9012878). The consultation is free, the price shown is the price paid, and there are no hidden fees. Payment options include Visa, Mastercard, Klarna and pay-monthly plans, with no subscription lock-in.

10 · Weight and metabolic changes

Weight and metabolic changes in trials

Weight results

In the SURMOUNT-1 trial of 2,539 adults, people taking tirzepatide alongside diet and exercise lost on average 15% of their body weight on 5mg, 19.5% on 10mg and 20.9% on 15mg over 72 weeks, compared with 3.1% with lifestyle changes alone.² These are trial averages. Individual results vary, and treatment works alongside a reduced-calorie diet and increased physical activity, not instead of them. At 72 weeks, 85% of participants on 5mg, 89% on 10mg and 91% on 15mg had lost at least 5% of their body weight. Half of participants on 10mg and 57% on 15mg lost at least 20% of their body weight.²

Trial averages do not predict your own result.

Beyond the scales

In trials, weight loss on tirzepatide came with average improvements in waist size, blood pressure, cholesterol and blood-sugar measures, and most participants with prediabetes returned to normal blood-sugar levels.² These are trial-average secondary outcomes, not promises of any kind. They are the reason prescribers talk about weight management as health management rather than appearance.

Connecting the dots carefully

It is natural to wonder whether better weight, blood pressure and blood sugar might help kidney health in the long run. That is a reasonable question for a clinician, who can look at your own readings.

If you are choosing treatment for weight management or type 2 diabetes, kidney safety is a screening question, not the headline. Either way, regular review is the safety net: ongoing monthly clinical reviews are part of our service, and your prescriber can discuss any new symptom.

Remember also that clearance takes time. Tirzepatide has a half-life of about five days, so after a final dose it takes roughly four to five weeks to clear the system. There is no way to speed this up, and nothing needs doing while it clears. If you stop because of a kidney or dehydration concern, talk to your clinician about next steps rather than waiting passively.¹

11 · Warning signs and safe use

Warning signs, safe use and storage

People often ask how to spot kidney trouble and what to do about it. A blood test and urine test, arranged by your GP, are how kidney function is checked.

When to seek advice

If you feel very unwell, are passing noticeably less urine than normal or have severe or persistent vomiting or diarrhoea, contact your clinical team and your GP, or use 111; if you cannot keep fluids down, contact your clinical team — dehydration needs medical help straight away. For anything severe, such as severe, persistent stomach pain, yellowing of the skin or eyes, or swelling of the face or throat, get medical help straight away.

Medicines and kidneys generally

Readers often ask which medicines are hard on the kidneys. That is a question for a pharmacist or your GP, who can check your own list. Tell every prescriber and pharmacist, including us, what you take, and ask before starting new regular medicines, including over-the-counter ones. Our consultation asks for your current medicines for exactly this reason.

Safe use of the pen

Mounjaro comes as a pre-filled multi-dose KwikPen used once weekly. Needles, a sharps bin and injection guidance are included with every order. Follow the pen's instructions each time. Once in use, a pen can be kept out of the fridge at a temperature not above 30°C for up to 30 days after first use, and must then be thrown away. Do not use a pen that has been above 30°C or frozen. Unopened pens should be stored in the fridge between 2–8°C until first use and keep until the printed expiry date; for questions on unopened pens out of the fridge, check the patient information leaflet and ask the pharmacy.¹³

Buying safely

Buy only from a regulated UK pharmacy that supplies on prescription after a consultation. Our supply comes directly from Eli Lilly's UK distribution via LillyDirect. The MHRA publishes counterfeit medicine alerts and runs the Yellow Card scheme, and anyone offering to supply without a consultation or prescription should be avoided.¹⁹

Track your progress

Our free companion app, GLPTrackr, helps you record your journey on iOS or Android, which can be handy when you see your GP or kidney team. Support is available Monday to Friday between 9am and 5pm by email at support@everydaymeds.co.uk, through the account portal chat or by phone on 0333 207 0413.

Mounjaro (tirzepatide) is a prescription-only medicine, supplied only after an online consultation reviewed by a GPhC-registered prescriber. It is used alongside a reduced-calorie diet and increased physical activity. Individual results vary. This page is information, not a substitute for medical advice.